These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 22511346)

  • 1. Interaction of lapatinib with cytochrome P450 3A5.
    Chan EC; New LS; Chua TB; Yap CW; Ho HK; Nelson SD
    Drug Metab Dispos; 2012 Jul; 40(7):1414-22. PubMed ID: 22511346
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanism-based inactivation of cytochrome P450 3A4 by lapatinib.
    Teng WC; Oh JW; New LS; Wahlin MD; Nelson SD; Ho HK; Chan EC
    Mol Pharmacol; 2010 Oct; 78(4):693-703. PubMed ID: 20624855
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytochrome P450 3A4 and CYP3A5-Catalyzed Bioactivation of Lapatinib.
    Towles JK; Clark RN; Wahlin MD; Uttamsingh V; Rettie AE; Jackson KD
    Drug Metab Dispos; 2016 Oct; 44(10):1584-97. PubMed ID: 27450182
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interindividual Variation in CYP3A Activity Influences Lapatinib Bioactivation.
    Bissada JE; Truong V; Abouda AA; Wines KJ; Crouch RD; Jackson KD
    Drug Metab Dispos; 2019 Nov; 47(11):1257-1269. PubMed ID: 31492693
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolism-dependent inhibition of CYP3A4 by lapatinib: evidence for formation of a metabolic intermediate complex with a nitroso/oxime metabolite formed via a nitrone intermediate.
    Barbara JE; Kazmi F; Parkinson A; Buckley DB
    Drug Metab Dispos; 2013 May; 41(5):1012-22. PubMed ID: 23404373
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolic intermediate complex formation of human cytochrome P450 3A4 by lapatinib.
    Takakusa H; Wahlin MD; Zhao C; Hanson KL; New LS; Chan EC; Nelson SD
    Drug Metab Dispos; 2011 Jun; 39(6):1022-30. PubMed ID: 21363997
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inactivation of Human Cytochrome P450 3A4 and 3A5 by Dronedarone and N-Desbutyl Dronedarone.
    Hong Y; Chia YM; Yeo RH; Venkatesan G; Koh SK; Chai CL; Zhou L; Kojodjojo P; Chan EC
    Mol Pharmacol; 2016 Jan; 89(1):1-13. PubMed ID: 26490246
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sorafenib and sunitinib, two anticancer drugs, inhibit CYP3A4-mediated and activate CY3A5-mediated midazolam 1'-hydroxylation.
    Sugiyama M; Fujita K; Murayama N; Akiyama Y; Yamazaki H; Sasaki Y
    Drug Metab Dispos; 2011 May; 39(5):757-62. PubMed ID: 21266595
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential Reversible and Irreversible Interactions between Benzbromarone and Human Cytochrome P450s 3A4 and 3A5.
    Tang LWT; Verma RK; Yong RP; Li X; Wang L; Lin Q; Fan H; Chan ECY
    Mol Pharmacol; 2021 Sep; 100(3):224-236. PubMed ID: 34210765
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanism-Based Inactivation of Cytochrome P450 3A4 by Benzbromarone.
    Tang LWT; Verma RK; Fan H; Chan ECY
    Mol Pharmacol; 2021 Apr; 99(4):266-276. PubMed ID: 33436520
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Studies on the role of metabolic activation in tyrosine kinase inhibitor-dependent hepatotoxicity: induction of CYP3A4 enhances the cytotoxicity of lapatinib in HepaRG cells.
    Hardy KD; Wahlin MD; Papageorgiou I; Unadkat JD; Rettie AE; Nelson SD
    Drug Metab Dispos; 2014 Jan; 42(1):162-71. PubMed ID: 24191259
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil.
    Wang YH; Jones DR; Hall SD
    Drug Metab Dispos; 2005 May; 33(5):664-71. PubMed ID: 15689501
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of Steroid Hormone Hydroxylations by and Docking to Human Cytochromes P450 3A4 and 3A5.
    Niwa T; Narita K; Okamoto A; Murayama N; Yamazaki H
    J Pharm Pharm Sci; 2019; 22(1):332-339. PubMed ID: 31339834
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective mechanism-based inactivation of CYP3A4 by CYP3cide (PF-04981517) and its utility as an in vitro tool for delineating the relative roles of CYP3A4 versus CYP3A5 in the metabolism of drugs.
    Walsky RL; Obach RS; Hyland R; Kang P; Zhou S; West M; Geoghegan KF; Helal CJ; Walker GS; Goosen TC; Zientek MA
    Drug Metab Dispos; 2012 Sep; 40(9):1686-97. PubMed ID: 22645092
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanism-based inactivation of CYP3A by HIV protease inhibitors.
    Ernest CS; Hall SD; Jones DR
    J Pharmacol Exp Ther; 2005 Feb; 312(2):583-91. PubMed ID: 15523003
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanism-based inactivation of CYP450 enzymes: a case study of lapatinib.
    Ho HK; Chan JC; Hardy KD; Chan EC
    Drug Metab Rev; 2015 Feb; 47(1):21-8. PubMed ID: 25639891
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification and characterization of the cytochrome P450 enzymes involved in N-dealkylation of propafenone: molecular base for interaction potential and variable disposition of active metabolites.
    Botsch S; Gautier JC; Beaune P; Eichelbaum M; Kroemer HK
    Mol Pharmacol; 1993 Jan; 43(1):120-6. PubMed ID: 8423765
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diltiazem inhibition of cytochrome P-450 3A activity is due to metabolite intermediate complex formation.
    Jones DR; Gorski JC; Hamman MA; Mayhew BS; Rider S; Hall SD
    J Pharmacol Exp Ther; 1999 Sep; 290(3):1116-25. PubMed ID: 10454485
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of human liver cytochrome P450 enzymes involved in the metabolism of SCH 530348 (Vorapaxar), a potent oral thrombin protease-activated receptor 1 antagonist.
    Ghosal A; Lu X; Penner N; Gao L; Ramanathan R; Chowdhury SK; Kishnani NS; Alton KB
    Drug Metab Dispos; 2011 Jan; 39(1):30-8. PubMed ID: 20926621
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The inactivation of cytochrome P450 3A5 by 17alpha-ethynylestradiol is cytochrome b5-dependent: metabolic activation of the ethynyl moiety leads to the formation of glutathione conjugates, a heme adduct, and covalent binding to the apoprotein.
    Lin HL; Hollenberg PF
    J Pharmacol Exp Ther; 2007 Apr; 321(1):276-87. PubMed ID: 17251390
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.